– Firefly’s AI foundation model, being built on more than 200,000 standardized EEG/ERP brain scans, bolsters its long-term BCI growth opportunity – – With over 3,000 Versus headsets shipped, the platform generates
– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS® System to Firefly’s nationwide network of Evoke™ clinicians – – Collaboration brings together an FDA-cleared pediatric ADHD treatment and
– This integration of Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial’s August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the
KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company advancing precision
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week – – These two peptides have attracted growing scientific interest for their
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the
- Firefly's total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters - - Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation
Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of Company's Commercial
Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive1 Firefly's AI-powered EEG/ERP technology may
GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker
NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Firefly Neuroscience, Inc. (NASDAQ:AIFF) on behalf of the company's shareholders. The investigation seeks to
KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health
– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly
